The continent of Africa stands at a fascinating juncture in clinical trials, presenting a blend of untapped potential and formidable challenges that must be addressed. This article dives into the complexities, challenges, developments, and opportunities within the dynamic field of clinical trials in Africa, juxtaposing the current state with global standards and uncovering the hurdles that must be surmounted to unlock the full potential of clinical research on the continent.

Navigating the Regulatory Landscape

The focus on endemic diseases is central to the discourse on clinical trials in Africa. While this addresses urgent health needs, the gap in clinical research in Africa, especially in non-communicable diseases (NCDs) compared to global benchmarks, is highlighted by a significant disparity in the number of publications and cohort studies focused on conditions like stroke and diabetes mellitus. This disparity indicates a need for increased investment in NCD research within the continent to better understand and address these growing health concerns​, particularly in areas such as non-communicable diseases, rare diseases, and gene therapies, compared to global benchmarks.

The path to this transformation is laden with challenges, including the pressing need for enhanced infrastructure, increased investment, and a more transparent regulatory framework. Overcoming the critical barriers of capacity building and the development of skilled professionals is essential.

Kenya’s Model of Success

Kenya’s progress in clinical trials is a testament to its effective regulatory frameworks, political commitment, and targeted funding. The country requires an independent review of research through its National Commission for Science, Technology, and Innovation (NACOSTI)-accredited ethics committees, ensuring that studies adhere to approved protocols and are conducted according to regulatory requirements and Good Clinical Practice (GCP) standards. This robust regulatory environment, overseen by the Pharmacy and Poisons Board and supported by ethical review from accredited institutions, highlights Kenya’s dedication to advancing clinical research in alignment with global standards. This has propelled Kenya to address significant healthcare needs and set a benchmark for sustainable research development. Similar advancements in nations like South Africa, Egypt, Morocco, and Tunisia highlight the critical role of governmental support in the healthcare sector. Yet, the widespread challenge of attracting and sustaining investment necessitates a collaborative approach to ensure the enduring growth of clinical trial policy and infrastructure in some of those countries.

Overcoming Investment Hesitancy

Sponsors’ reluctance to invest in clinical trials in Africa seems to stem from pragmatic concerns, such as inadequate infrastructure, a shortage of skilled professionals, and complex regulatory landscapes. Addressing these issues head-on is imperative to making African nations appealing destinations for clinical research investment. Enhancing infrastructure, investing in education and training, and streamlining regulatory processes are vital steps toward bolstering investor confidence.

A supportive political environment is indispensable in nurturing a culture of research and innovation. Showcasing countries as favorable environments for clinical research through initiatives like incentives for research and development, establishing international research partnerships, and promoting local research capabilities can significantly alter investor perceptions.

The Infrastructure Quandary

The infrastructure supporting clinical trials across Africa varies significantly, with countries like South Africa, Egypt, Morocco, and Tunisia leading the way due to their advanced medical facilities and countries like Kenya with supportive clinical trial policies. However, many countries on the continent still face considerable challenges, including scarce resources, inadequate healthcare facilities, and less developed regulatory environments. A detailed account from a study in Malawi (the Malawi Cryptosporidium study) provides a tangible example of these challenges, including operational and regulatory hurdles, limited physical space, unreliable internet connectivity, and extensive training and equipment procurement​​.

Efforts to expand clinical trials in Africa highlight the importance of strengthening regulatory systems and operational capabilities. Only about 2% of clinical trials are conducted in Africa, with 70% of these trials concentrated in just three countries. This emphasizes the need for increased investment in healthcare and research infrastructure and the development of international partnerships to enhance the clinical trial landscape continent-wide​.

Addressing these issues requires harmonization and centralization of standards and processes, improved communication about and access to regulatory and ethics processes, and greater use of technology. Initiatives like the Clinical Trials Community platform developed by the African Academy of Sciences, with support from the Bill & Melinda Gates Foundation, aim to increase visibility for African clinical trialists and research sites and make regulatory and ethics procedures more transparent and accessible​​.

Bridging the Skills Gap

A critical challenge facing the continent’s aspirations in clinical research is the gap in adequately trained professionals, particularly in GCP. This shortage impacts research quality, efficiency, and global compliance. Addressing this issue requires a concerted effort in education, professional development, and policy reform. Initiatives might include specialized training programs, partnerships with international research institutions, and incentives to retain talent within the continent.

Africa’s Advantage: Diversity and Market Potential

Thanks to its immense diversity and untapped market potential, Africa offers a unique clinical research opportunity. The continent’s varied genetic, environmental, and lifestyle factors make it an invaluable setting for studying the efficacy and safety of novel treatments across diverse populations. With a population expected to nearly double by 2050, Africa also represents a significant market for biopharmaceutical innovations, especially for diseases in the continent. This dual appeal of genetic diversity and market potential makes Africa an ideal location for clinical trials, offering insights crucial for global health advancements while tapping into new markets for pharmaceutical breakthroughs that are unique to the African population.


As we navigate these hurdles, the potential for clinical trials in Africa to significantly contribute to global health knowledge and innovation becomes increasingly evident. With a commitment to sustained investment and international collaboration, Africa can align with global research standards, offering unique insights into diverse health challenges and marking a new chapter in clinical trials.

author avatar
Moe Alsumidaie Chief Editor
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.